Veloxis
139 articles with Veloxis
-
Biohope and C. Alan Foundation Named Winners of the 2022 Lyfebulb-Veloxis Innovation Challenge: Transforming Organ Transplantation
10/17/2022
Lyfebulb and Veloxis Pharmaceuticals are excited to announce that Biohope was selected as the winner of the Innovation Award and C. Alan Foundation as the winner of the Impact Award at the 2022 Lyfebulb-Veloxis Innovation Challenge: Transforming Organ Transplantation.
-
Lyfebulb and Veloxis Pharmaceuticals Announce Finalists for 2022 Innovation Challenge in Organ Transplantation
9/19/2022
Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, are pleased to announce 10 finalists for the 2022 "Transforming Organ Transplantation Through Innovation" Challenge.
-
Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
6/28/2022
Veloxis Pharmaceuticals, an Ashai Kasei company, today announced dosing of the first patient by its partner, Xenikos, in a global pivotal Phase 3 clinical study.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Investigational Drug for Kidney Transplant Immunosuppression
5/18/2022
Veloxis Pharmaceuticals, Inc. , an Asahi Kasei company, today announced that the first participant has been dosed in a Phase 1 Study of VEL-101 [ NCT05238493 ]. VEL-101 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.
-
Veloxis Pharmaceuticals' VEL-101 Granted FDA Fast Track Designation
2/17/2022
Veloxis Pharmaceuticals Inc., an Asahi Kasei company, today announced that VEL-101, a novel investigational maintenance immunosuppressive agent being developed for prophylaxis of renal allograft rejection in patients receiving a kidney transplant, was granted fast track designation by the U.S. Food & Drug Administration (FDA).
-
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor
9/8/2021
Xenikos B.V., a clinical-stage biopharmaceutical company currently developing a novel therapy for treating immune related disorders, announced the closing of €40 million in convertible debt consisting of two equal tranches of €20 million.
-
OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104
4/26/2021
Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients. OSE Immunotherapeutics to receive up to €315 million in potential milestones, including a €7 million upfront, and tiered royalties on sales.
-
Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis
11/25/2019
Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis
-
Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2019
11/12/2019
Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim Report for the first nine months of 2019.
-
Veloxis Increases Outlook for 2019 Based on Continued Strong Performance
10/31/2019
Veloxis Pharmaceuticals A/S announced that it is raising its Outlook for 2019.
-
Veloxis Revises Outlook for 2019 Based on Strong Performance
7/22/2019
Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that it is raising its Outlook for 2019
-
Envarsus XR® to be Subject of Upcoming Presentations at 2019 American Transplant Congress
5/31/2019
Veloxis Pharmaceuticals announced that the Company's product, Envarsus XR, will be the subject of two oral and fifteen poster presentations at the American Transplant Congress June 1st-5th, 2019 in Boston, Massachusetts, USA.
-
Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2019
5/6/2019
Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim Report for the first three months of 2019.
-
Notice to Convene Annual General Meeting 2019
3/12/2019
The board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67, hereby convenes the annual general meeting in the Company which will be held on
-
Veloxis Pharmaceuticals Releases Annual Report for 2018
2/27/2019
Veloxis Pharmaceuticals A/S (OMX: VELO) today releases its Annual Report for the financial year 2018.
-
Mark Hensley Promoted to Chief Commercial Officer of Veloxis Pharmaceuticals
1/3/2019
Veloxis Pharmaceuticals A/S today announces the promotion of Mark Hensley to Chief Commercial Officer.
-
FDA Approves New Indication for ENVARSUS XR® (tacrolimus extended-release tablets)
12/19/2018
Veloxis Pharmaceuticals announced today that the U.S. Food & Drug Administration (FDA) approved a new indication for Envarsus XR (tacrolimus extended-release tablets) to prevent organ rejection in de novo kidney transplant patients in combination with other immunosuppressants.
-
Ira Duarte Promoted to Chief Financial Officer of Veloxis Pharmaceuticals A/S
10/31/2018
Veloxis Pharmaceuticals A/S today announces the promotion of Ira Duarte to Chief Financial Officer. Ms. Duarte has served as the vice-president of finance for Veloxis Pharmaceuticals, Inc. since February 2016 where she has been responsible for all finance and accounting related functions including financial reporting, treasury, budgeting and tax.
-
Veloxis to Present at the Jefferies 2018 London Healthcare Conference
10/10/2018
Veloxis Pharmaceuticals A/S announced today that CEO Craig Collard will present at the Jefferies 2018 London Healthcare Conference at 8:00 AM GMT on Thursday, November 15, 2018.